| answer text |
<p>The National Institute for Health and Care Excellence (NICE) is in the process
of scoping the review of the methods for technology appraisal and highly specialised
technologies evaluations. Scoping will involve patient organisations and other relevant
stakeholders, including industry. The Voluntary Scheme for Branded Medicines Pricing
and Access sets out the Department’s expectation that that any future changes to NICE
methods and processes would support faster adoption of the most clinically and cost
effective medicines. Additional detail and more information will be made available
on the NICE website in due course.</p><p>The 2019 Voluntary Scheme also states that
NICE will adopt the principle of appraisal timelines for non-oncology treatments matching
the faster timescales for oncology treatments, subject to the evidence base for the
product being sufficiently developed to enable a NICE appraisal with the same level
of rigour and certainty as would be expected currently.</p>
|
 |
